chromosome 16 open reading frame 78Genealiases: []
Q-omics provides the consensus-scored C16orf78 profile across patient tissues and cancer cell-line models. C16orf78 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, C16orf78 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, C16orf78 RNA expression shows 6,807 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, LUAD, and STAD as cancer lineages where C16orf78 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C16orf78 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C16orf78 survival associations across molecular data types. C16orf78 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C16orf78 RNA expression–survival associations across cancer types. High C16orf78 expression shows unfavorable associations in CHOL, READ, DLBC, LUAD and ACC, but favorable associations in BLCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for C16orf78 RNA expression.
This table summarizes C16orf78 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for C16orf78. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C16orf78 shows lower tumor expression in LUAD, LUSC, THCA, BRCA and COAD and higher tumor expression in KIRC. The LUAD box plot shows higher C16orf78 RNA expression in normal versus tumor tissue (log2 FC = −0.203, t-test p < 0.001).
This table shows molecular features associated with C16orf78 in patient tissues and cancer cell lines. In patient samples, C16orf78 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, C16orf78 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
